HRP20180064T1 - Cjepiva s kapsularnim biokonjugatima iz gram-pozitivnih bakterija - Google Patents
Cjepiva s kapsularnim biokonjugatima iz gram-pozitivnih bakterija Download PDFInfo
- Publication number
- HRP20180064T1 HRP20180064T1 HRP20180064TT HRP20180064T HRP20180064T1 HR P20180064 T1 HRP20180064 T1 HR P20180064T1 HR P20180064T T HRP20180064T T HR P20180064TT HR P20180064 T HRP20180064 T HR P20180064T HR P20180064 T1 HRP20180064 T1 HR P20180064T1
- Authority
- HR
- Croatia
- Prior art keywords
- staphylococcus aureus
- bacterium
- bacteria
- gram
- prokaryotic organism
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims 8
- 241000192125 Firmicutes Species 0.000 title claims 2
- 241000191967 Staphylococcus aureus Species 0.000 claims 18
- 150000004676 glycans Chemical class 0.000 claims 8
- 229920001282 polysaccharide Polymers 0.000 claims 8
- 239000005017 polysaccharide Substances 0.000 claims 8
- 241000894006 Bacteria Species 0.000 claims 6
- 108090000623 proteins and genes Proteins 0.000 claims 5
- 102000004169 proteins and genes Human genes 0.000 claims 5
- 108091035707 Consensus sequence Proteins 0.000 claims 4
- 239000002773 nucleotide Substances 0.000 claims 4
- 125000003729 nucleotide group Chemical group 0.000 claims 4
- 108700023372 Glycosyltransferases Proteins 0.000 claims 3
- 102000051366 Glycosyltransferases Human genes 0.000 claims 3
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims 3
- 239000002671 adjuvant Substances 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 3
- OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical group C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 claims 2
- 101710092462 Alpha-hemolysin Proteins 0.000 claims 2
- 108010089072 Dolichyl-diphosphooligosaccharide-protein glycotransferase Proteins 0.000 claims 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 2
- 230000004520 agglutination Effects 0.000 claims 2
- 239000002095 exotoxin Substances 0.000 claims 2
- 231100000776 exotoxin Toxicity 0.000 claims 2
- 231100000699 Bacterial toxin Toxicity 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 claims 1
- 108091006036 N-glycosylated proteins Proteins 0.000 claims 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 claims 1
- 239000000688 bacterial toxin Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 108700014210 glycosyltransferase activity proteins Proteins 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 229960003085 meticillin Drugs 0.000 claims 1
- 239000011859 microparticle Substances 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 239000007764 o/w emulsion Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229930182490 saponin Natural products 0.000 claims 1
- 150000007949 saponins Chemical class 0.000 claims 1
- 235000017709 saponins Nutrition 0.000 claims 1
- 239000000277 virosome Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1025—Acyltransferases (2.3)
- C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/034—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the periplasmic space of Gram negative bacteria as a soluble protein, i.e. signal sequence should be cleaved
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Claims (14)
1. Gram-negativni prokariotski organizam kao domaćin, naznačen time što je navedeni prokariotski organizam kao domaćin bakterija E. coli, koja sadrži:
(i) nukleotidni slijed koji kodira najmanje jednu glikozil-transferazu iz Gram-pozitivne bakterije, gdje je navedena Gram-pozitivna bakterija Staphylococcus aureus;
(ii) nukleotidni slijed koji kodira najmanje jednu glikozil-transferazu iz Gram-negativne bakterije, gdje je navedena Gram-negativna bakterija Pseudomonas aeruginosa;
(iii) nukleotidni slijed koji kodira proteinski nosač, gdje navedeni proteinski nosač sadrži aminokiselinski konsenzusni slijed D/E-X-N-Z-S/T, gdje X i Z mogu biti bilo koja prirodna aminokiselina osim prolina; i
(iv) nukleotidni slijed koji kodira oligosaharil-transferazu.
2. Prokariotski organizam kao domaćin u skladu s patentnim zahtjevom 1, naznačen time što je navedena bakterija Staphylococcus aureus soj s kapsularnim polisaharidom 5 ili soj s kapsularnim polisaharidom 8.
3. Prokariotski organizam kao domaćin u skladu s patentnim zahtjevom 1 ili 2, naznačen time što je navedena bakterija Staphilococus aureus soj otporan na meticilin.
4. Prokariotski organizam kao domaćin u skladu s bilo kojim od patentnih zahtjeva 1-3, naznačen time što sadrži najmanje dva glikozil-transferaze iz različitih sojeva Gram-pozitivne bakterije.
5. Prokariotski organizam kao domaćin u skladu s bilo kojim od patentnih zahtjeva 1-4, naznačen time što je navedeni proteinski nosač egzotoksin iz bakterije Pseudomonas aeruginosa, alfa hemolizin iz bakterije Staphylococcus aureus ili aglutinacijski čimbenik A iz bakterije Staphylococcus aureus.
6. Prokariotski organizam kao domaćin u skladu s bilo kojim od patentnih zahtjeva 1-5, naznačen time što je navedena oligosaharil-transferaza iz bakterije Campilobacter jejuni.
7. Postupak dobivanja rekombinantnog N-glikoziliranog proteina, naznačen time što se upotrebljava prokariotski organizam kao domaćin u skladu s bilo kojim od patentnih zahtjeva 1-6.
8. Cjepivo protiv bakterije Staphylococcus aureus, naznačeno time što sadrži:
protein koji sadrži ubačeni konsenzusni slijed D/E-X-N-Z-S/T, gdje X i Z mogu biti bilo koja prirodna aminokiselina osim prolina;
najmanje jedan polisaharid iz bakterije Staphylococcus aureus, povezan s navedenim konsenzusnim slijedom N-glikozidnom spojnicom; i,
izborno, farmaceutski prihvatljiv nosač ili adjuvans.
9. Cjepivo protiv bakterije Staphylococcus aureus u skladu s patentnim zahtjevom 8, naznačeno time što sadrži adjuvans.
10. Cjepivo protiv bakterije Staphylococcus aureus u skladu s patentnim zahtjevom 9, naznačeno time što adjuvans sadrži aluminijeve soli, emulzije, poput emulzije ulja u vodi (MF59, AS03), kombinacije lipida i sol (AS04), ISCOMS, liposome/virosome, nano- i mikročestice, saponine (QS21), MPL A, citokine, derivate DNA ili bakterijske toksine.
11. Cjepivo protiv bakterije Staphylococcus aureus u skladu s bilo kojim od patentnih zahtjeva 8-10, naznačeno time što sadrži dva ili više navedenih ubačenih konsenzusnih sljedova i dva ili više navedenih polisaharida iz bakterije Staphylococcus aureus.
12. Cjepivo protiv bakterije Staphylococcus aureus u skladu s bilo kojim od patentnih zahtjeva 8-11, naznačeno time što navedeni najmanje jedan polisaharid iz bakterije Staphylococcus aureus sadrži kapsularni polisaharid 5 ili kapsularni polisaharid 8.
13. Cjepivo protiv bakterije Staphylococcus aureus u skladu s patentnim zahtjevom 12, naznačeno time što je navedeni protein egzotoksin iz bakterije Pseudomonas aeruginosa, ili alfa hemolizin iz bakterije Staphylococcus aureus, ili aglutinacijski čimbenik A iz bakterije Staphylococcus aureus.
14. Cjepivo protiv bakterije Staphylococcus aureus u skladu s patentnim zahtjevom 13, naznačeno time što navedeni najmanje jedan polisaharid iz bakterije Staphylococcus aureus sadrži strukturu:
(A)
[image]
ili
(B)
[image]
.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33217010P | 2010-05-06 | 2010-05-06 | |
| PCT/EP2011/057111 WO2011138361A1 (en) | 2010-05-06 | 2011-05-04 | Capsular gram-positive bacteria bioconjugate vaccines |
| EP11724567.0A EP2566507B1 (en) | 2010-05-06 | 2011-05-04 | Capsular gram-positive bacteria bioconjugate vaccines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20180064T1 true HRP20180064T1 (hr) | 2018-02-23 |
Family
ID=44902091
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20180064TT HRP20180064T1 (hr) | 2010-05-06 | 2018-01-15 | Cjepiva s kapsularnim biokonjugatima iz gram-pozitivnih bakterija |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US8871491B2 (hr) |
| EP (2) | EP3281639B1 (hr) |
| JP (2) | JP6339366B2 (hr) |
| KR (2) | KR101916290B1 (hr) |
| CN (1) | CN103079591B (hr) |
| AU (2) | AU2011249839B2 (hr) |
| CA (1) | CA2798381C (hr) |
| CY (1) | CY1119895T1 (hr) |
| DK (1) | DK2566507T3 (hr) |
| ES (2) | ES2657588T3 (hr) |
| HR (1) | HRP20180064T1 (hr) |
| HU (1) | HUE037956T2 (hr) |
| IL (1) | IL222711B (hr) |
| LT (1) | LT2566507T (hr) |
| NO (1) | NO2566507T3 (hr) |
| PL (1) | PL2566507T3 (hr) |
| PT (1) | PT2566507T (hr) |
| SG (1) | SG185433A1 (hr) |
| SI (1) | SI2566507T1 (hr) |
| WO (1) | WO2011138361A1 (hr) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1481057B1 (en) * | 2002-03-07 | 2006-02-15 | Eidgenössische Technische Hochschule Zürich | System and method for the production of recombinant glycosylated proteins in a prokaryotic host |
| EP3427749A1 (en) | 2008-02-20 | 2019-01-16 | GlaxoSmithKline Biologicals SA | Bioconjugates made from recombinant n-glycosylated proteins from procaryotic cells |
| TR201803015T4 (tr) | 2009-11-19 | 2018-03-21 | Glaxosmithkline Biologicals Sa | Prokaryotik hücrelerde immünojenik polisakaridler üreten biyosentetik sistem. |
| US9526775B2 (en) | 2012-04-27 | 2016-12-27 | Washington University | Glycoengineered outer membrane vesicles and use thereof as vaccines |
| JP2015522692A (ja) | 2012-07-16 | 2015-08-06 | ファイザー・インク | 糖およびその使用 |
| BR112015001390B1 (pt) | 2012-07-26 | 2024-04-30 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc | Proteína de fusão, ácido nucleico isolado e uso de uma composição de vacina |
| TR201904022T4 (tr) | 2012-10-12 | 2019-04-22 | Glaxosmithkline Biologicals Sa | Konakçı hücre modifikasyon yöntemleri. |
| EP2917351B1 (en) | 2012-11-07 | 2018-12-19 | GlaxoSmithKline Biologicals S.A. | Production of recombinant vaccine in e. coli by enzymatic conjugation |
| US9931392B2 (en) | 2013-01-18 | 2018-04-03 | London School Of Hygiene And Tropical Medicine | Glycosylation method |
| GB201301085D0 (en) | 2013-01-22 | 2013-03-06 | London School Hygiene & Tropical Medicine | Glycoconjugate Vaccine |
| SG11201602546RA (en) * | 2013-10-11 | 2016-04-28 | Glycovaxyn Ag | Methods of host cell modification |
| JP2016540764A (ja) * | 2013-12-04 | 2016-12-28 | グリコヴァキシン アーゲー | 大腸菌で合成された糖タンパク質ワクチンによる黄色ブドウ球菌感染の予防 |
| SI3131577T1 (sl) * | 2014-04-17 | 2020-08-31 | Glaxosmithkline Biologicals S.A. | Modificirane gostiljske celice in uporabe le-teh |
| US10307474B2 (en) * | 2014-08-08 | 2019-06-04 | Glaxosmithkline Biologicals S.A. | Modified host cells and hybrid oligosaccharides for use in bioconjugate production |
| US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
| AU2015342943B2 (en) * | 2014-11-05 | 2018-06-28 | The United States Of America As Represented By The Secretary Of The Navy | Synthetic antigen constructs against Campylobacter jejuni |
| US10500261B2 (en) | 2014-11-05 | 2019-12-10 | The United States Of America As Represented By The Secretary Of The Navy | Synthetic antigen constructs against campylobacter jejuni |
| PT3240895T (pt) | 2014-12-30 | 2022-03-02 | Glaxosmithkline Biologicals Sa | Composições e métodos para glicosilação de proteínas |
| WO2017001586A1 (en) * | 2015-07-01 | 2017-01-05 | Glaxosmithkline Biologicals S.A. | Immunogenic compositions |
| GB201518668D0 (en) | 2015-10-21 | 2015-12-02 | Glaxosmithkline Biolog Sa | Immunogenic Comosition |
| GB201610599D0 (en) | 2016-06-17 | 2016-08-03 | Glaxosmithkline Biologicals Sa | Immunogenic Composition |
| US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| GB201712678D0 (en) | 2017-08-07 | 2017-09-20 | Glaxosmithkline Biologicals Sa | Process for the manipulation of nucleic acids |
| GB201721576D0 (en) | 2017-12-21 | 2018-02-07 | Glaxosmithkline Biologicals Sa | Hla antigens and glycoconjugates thereof |
| GB201721582D0 (en) * | 2017-12-21 | 2018-02-07 | Glaxosmithkline Biologicals Sa | S aureus antigens and immunogenic compositions |
| CN108330142B (zh) * | 2018-02-09 | 2021-09-17 | 河北科技师范学院 | 一种具有免疫保护作用的美人鱼发光杆菌溶血素Hlych蛋白 |
| GB201802339D0 (en) * | 2018-02-13 | 2018-03-28 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
| US11260119B2 (en) | 2018-08-24 | 2022-03-01 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| CN109400704B (zh) * | 2018-11-14 | 2020-07-21 | 珠海泰诺麦博生物技术有限公司 | 一种抗金黄色葡萄球菌α-溶血素的抗体及其应用 |
| US20220054632A1 (en) | 2018-12-12 | 2022-02-24 | Glaxosmithkline Biologicals Sa | Modified carrier proteins for o-linked glycosylation |
| JP2022517981A (ja) * | 2019-01-11 | 2022-03-11 | ノースウェスタン ユニバーシティ | 原核細胞溶解物におけるバイオコンジュゲートワクチンの合成 |
| EP3757217A1 (en) | 2019-06-27 | 2020-12-30 | GlaxoSmithKline Biologicals S.A. | Methods for protein purification |
| EP3770269A1 (en) | 2019-07-23 | 2021-01-27 | GlaxoSmithKline Biologicals S.A. | Quantification of bioconjugate glycosylation |
| EP3777884A1 (en) | 2019-08-15 | 2021-02-17 | GlaxoSmithKline Biologicals S.A. | Immunogenic composition |
| CN112575041B (zh) * | 2019-09-30 | 2022-12-13 | 江南大学 | 一种混合碳源高效发酵生产phb的工程菌及其应用 |
| CA3185642A1 (en) | 2020-06-25 | 2021-12-30 | Glaxosmithkline Biologicals Sa | Modified exotoxin a proteins |
| CN114085255B (zh) * | 2020-08-24 | 2023-08-29 | 山东大学 | 一种苏黎世克罗诺杆菌5型脂多糖o-抗原寡糖片段及其制备方法与应用 |
| WO2022171679A2 (en) | 2021-02-11 | 2022-08-18 | Glaxosmithkline Biologicals Sa | Protein |
| WO2023118033A1 (en) | 2021-12-22 | 2023-06-29 | Glaxosmithkline Biologicals Sa | Vaccine |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1900A (en) | 1840-12-14 | Machine for extracting stumps | ||
| ATE67786T1 (de) | 1984-08-01 | 1991-10-15 | Boehringer Ingelheim Int | Neue genetische sequenzen, die durch sie codierten interferon-peptide vom typ i und diese sie produzierende organismen. |
| US5643758A (en) | 1987-03-10 | 1997-07-01 | New England Biolabs, Inc. | Production and purification of a protein fused to a binding protein |
| WO1994026906A2 (en) | 1993-05-14 | 1994-11-24 | The Upjohn Company | CLONED DNA ENCODING A UDP-GALNAc:POLYPEPTIDE,N-ACETYLGALACTOS AMINYLTRANSFERASE |
| US6503744B1 (en) | 1999-02-01 | 2003-01-07 | National Research Council Of Canada | Campylobacter glycosyltransferases for biosynthesis of gangliosides and ganglioside mimics |
| CA2363297C (en) | 1999-03-02 | 2011-08-09 | Michael J. Betenbaugh | Engineering intracellular sialylation pathways |
| US20020019342A1 (en) | 2000-05-12 | 2002-02-14 | Robert Bayer | In vitro modification of glycosylation patterns of recombinant glycopeptides |
| CA2411968C (en) | 2000-06-30 | 2009-12-15 | Flanders Interuniversity Institute For Biotechnology (Vib) | Protein glycosylation modification in pichia pastoris |
| EP1481057B1 (en) | 2002-03-07 | 2006-02-15 | Eidgenössische Technische Hochschule Zürich | System and method for the production of recombinant glycosylated proteins in a prokaryotic host |
| US20040265954A1 (en) | 2002-03-07 | 2004-12-30 | Markus Aebi | System and method for the production of recombinant proteins |
| US7598354B2 (en) | 2002-08-01 | 2009-10-06 | National Research Council Of Canada | Campylobacter glycans and glycopeptides |
| EP1756149B1 (en) | 2004-05-24 | 2013-09-04 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Live, oral vaccine for protection against shigella dysenteriae serotype 1 |
| EP1888761B1 (en) | 2005-05-11 | 2010-09-29 | ETH Zurich | Recombinant n-glycosylated proteins from procaryotic cells |
| EP2476433A1 (en) | 2006-03-30 | 2012-07-18 | GlaxoSmithKline Biologicals S.A. | Immunogenic composition |
| US20100286067A1 (en) * | 2008-01-08 | 2010-11-11 | Biogenerix Ag | Glycoconjugation of polypeptides using oligosaccharyltransferases |
| EP3427749A1 (en) * | 2008-02-20 | 2019-01-16 | GlaxoSmithKline Biologicals SA | Bioconjugates made from recombinant n-glycosylated proteins from procaryotic cells |
-
2011
- 2011-05-04 EP EP17192866.6A patent/EP3281639B1/en active Active
- 2011-05-04 LT LTEP11724567.0T patent/LT2566507T/lt unknown
- 2011-05-04 PL PL11724567T patent/PL2566507T3/pl unknown
- 2011-05-04 JP JP2013508489A patent/JP6339366B2/ja active Active
- 2011-05-04 NO NO11724567A patent/NO2566507T3/no unknown
- 2011-05-04 ES ES11724567.0T patent/ES2657588T3/es active Active
- 2011-05-04 AU AU2011249839A patent/AU2011249839B2/en active Active
- 2011-05-04 US US13/100,603 patent/US8871491B2/en active Active
- 2011-05-04 CA CA2798381A patent/CA2798381C/en active Active
- 2011-05-04 ES ES17192866T patent/ES2844596T3/es active Active
- 2011-05-04 SG SG2012081535A patent/SG185433A1/en unknown
- 2011-05-04 DK DK11724567.0T patent/DK2566507T3/da active
- 2011-05-04 EP EP11724567.0A patent/EP2566507B1/en active Active
- 2011-05-04 WO PCT/EP2011/057111 patent/WO2011138361A1/en active Application Filing
- 2011-05-04 KR KR1020187004586A patent/KR101916290B1/ko active IP Right Grant
- 2011-05-04 CN CN201180033560.1A patent/CN103079591B/zh active Active
- 2011-05-04 HU HUE11724567A patent/HUE037956T2/hu unknown
- 2011-05-04 SI SI201131403T patent/SI2566507T1/en unknown
- 2011-05-04 KR KR1020127031847A patent/KR20130063510A/ko active Search and Examination
- 2011-05-04 PT PT117245670T patent/PT2566507T/pt unknown
-
2012
- 2012-10-25 IL IL222711A patent/IL222711B/en active IP Right Grant
-
2014
- 2014-09-23 US US14/494,150 patent/US9585950B2/en active Active
-
2016
- 2016-07-25 AU AU2016208265A patent/AU2016208265A1/en not_active Abandoned
- 2016-10-06 JP JP2016197813A patent/JP6435583B2/ja active Active
-
2017
- 2017-01-25 US US15/414,900 patent/US10307473B2/en active Active
-
2018
- 2018-01-15 HR HRP20180064TT patent/HRP20180064T1/hr unknown
- 2018-02-06 CY CY20181100148T patent/CY1119895T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20180064T1 (hr) | Cjepiva s kapsularnim biokonjugatima iz gram-pozitivnih bakterija | |
| HRP20160276T1 (hr) | Pripravci za imuniziranje protiv bakterije staphylococcus aureus | |
| EP2545068B8 (en) | Immunogenic composition or vaccine against gram-negative bacterial, for example neiserial, infection or disease | |
| RU2017104529A (ru) | Композиции neisseria meningitidis и способы их применения | |
| HRP20180216T1 (hr) | Fuzijski proteini i kombinacijska cjepiva koja sadrže protein e i pilin a iz bakterije haemophilus influenzae | |
| WO2015024668A3 (en) | Respiratory syncytial virus (rsv) vaccine | |
| HRP20190907T1 (hr) | Imunogeni pripravak koji sadrži polipeptide iz panton-valentin leukocidina (pvl) | |
| BR112012022688A2 (pt) | proteína de fusão, vesícula da membrana externa isolada, polinucleotídeo, composição farmacêutica, vacina, método para tratamento ou prevenção de infecção ou doença por neisseria, uso e método para fabricar uma proteína de fusão | |
| JP2013524844A5 (hr) | ||
| HRP20191166T1 (hr) | Stabilizirani proteini, namijenjeni imuniziranju protiv bakterije staphylococcus aureus | |
| WO2008073891A3 (en) | Salmonella vaccine in poultry | |
| WO2011004263A3 (en) | Conserved escherichia coli immunogens | |
| BR112014032636A2 (pt) | Vacinas atenuadas de streptococcus suis e métodos de produção e usos das mesmas | |
| Sun et al. | Pseudomonas fluorescens: iron-responsive proteins and their involvement in host infection | |
| MX2012003827A (es) | Toxina rtx citolitica de gallibacterium anatis. | |
| CO2021001926A2 (es) | Composiciones de escherichia coli y métodos de estas | |
| WO2009077577A3 (en) | Vaccine antigens from piscirickettsia salmonis | |
| HRP20180039T1 (hr) | Antigeni pseudomonasa i kombinacije antigena | |
| HRP20191864T1 (hr) | Imunogeni pripravci protiv bakterije clostridium difficile | |
| WO2012009774A3 (pt) | Microrganismos recombinantes, métodos de preparação de linhagens vacinais, antígenos, composições vacinais vetorizadas, seus usos, anticorpos, kit de diagnóstico e métodos de tratamento e/ou profilaxia | |
| WO2011025344A3 (ko) | 소의 병원성 대장균의 부착인자가 형질전환된 약독화 살모넬라균 변이주 및 이를 포함하는 소의 대장균증 및 살모넬라균증의 예방 및 치료용 백신조성물 | |
| WO2018083490A3 (en) | Capped oligosaccharides comprising seven or more units of 4,6-dideoxy-4-acylamido-alpha-pyranose and conjugates thereof as vaccines against infections caused by brucella organisms | |
| WO2010046778A3 (en) | Novel shigella frotein antigens and methods | |
| Kumar et al. | Comparative immune response of purified native OmpH protein derived from Pasteurella multocida P52 and oil adjuvant vaccine against hemorrhagic septicemia in mice | |
| WO2009014382A3 (en) | Cxcl11 adjuvant compositions and uses thereof |